JP2024529009A - セロトニン再取り込み阻害剤離脱症候群の治療 - Google Patents

セロトニン再取り込み阻害剤離脱症候群の治療 Download PDF

Info

Publication number
JP2024529009A
JP2024529009A JP2024506806A JP2024506806A JP2024529009A JP 2024529009 A JP2024529009 A JP 2024529009A JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024506806 A JP2024506806 A JP 2024506806A JP 2024529009 A JP2024529009 A JP 2024529009A
Authority
JP
Japan
Prior art keywords
escitalopram
gentisate
subject
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529009A5 (cg-RX-API-DMAC7.html
Inventor
マーク・ヘースルトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2024529009A publication Critical patent/JP2024529009A/ja
Publication of JP2024529009A5 publication Critical patent/JP2024529009A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
JP2024506806A 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療 Pending JP2024529009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (2)

Publication Number Publication Date
JP2024529009A true JP2024529009A (ja) 2024-08-01
JP2024529009A5 JP2024529009A5 (cg-RX-API-DMAC7.html) 2025-06-19

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506806A Pending JP2024529009A (ja) 2021-07-06 2022-07-06 セロトニン再取り込み阻害剤離脱症候群の治療

Country Status (8)

Country Link
US (1) US20240277654A1 (cg-RX-API-DMAC7.html)
EP (1) EP4366726A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529009A (cg-RX-API-DMAC7.html)
KR (1) KR20240117521A (cg-RX-API-DMAC7.html)
CN (1) CN118284414A (cg-RX-API-DMAC7.html)
AU (1) AU2022308198A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227324A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023281406A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509436A (ja) * 2015-03-26 2018-04-05 レ ラボラトワール セルヴィエ 8−シクロプロピル−3−[2−(3−フルオロフェニル)エチル]−7,8−ジヒドロ−3h−[1,3]オキサジノ[6,5−g][1,2,3]ベンゾトリアジン−4,9−ジオンと抗うつ剤との新規な組み合わせ、及びそれを含有する医薬組成物
WO2018135839A1 (ko) * 2017-01-17 2018-07-26 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
JP2020536961A (ja) * 2017-10-09 2020-12-17 テヴァ ファーマシューティカル インダストリーズ リミテッド エスシタロプラムの新しい塩および固体形態
JP2021501209A (ja) * 2017-11-01 2021-01-14 コリア リサーチ インスティチュート オブ ケミカル テクノロジー エスシタロプラムを含む微粒球状徐放出注射剤及びその製造方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE410186T1 (de) 2003-06-26 2008-10-15 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
EP2054073B1 (en) 2006-07-11 2014-11-26 Foresee Pharmaceuticals, Inc. Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
WO2010040188A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
WO2011080733A1 (en) 2010-01-04 2011-07-07 Mapi Pharma Limited Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
SI2394663T1 (sl) 2010-05-31 2022-02-28 Laboratorios Farmaceuticos Rovi, S.A. Sestave za injicirane biološko razgradljive vsadke in situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
WO2013063125A1 (en) 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
JP6282231B2 (ja) 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドAllergan,Incorporated 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
PT3010962T (pt) 2013-06-20 2017-09-05 Pharmathen Sa Preparação de micropartículas polilactida-poliglicolida com um perfil de libertação sigmoide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509436A (ja) * 2015-03-26 2018-04-05 レ ラボラトワール セルヴィエ 8−シクロプロピル−3−[2−(3−フルオロフェニル)エチル]−7,8−ジヒドロ−3h−[1,3]オキサジノ[6,5−g][1,2,3]ベンゾトリアジン−4,9−ジオンと抗うつ剤との新規な組み合わせ、及びそれを含有する医薬組成物
WO2018135839A1 (ko) * 2017-01-17 2018-07-26 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
JP2020536961A (ja) * 2017-10-09 2020-12-17 テヴァ ファーマシューティカル インダストリーズ リミテッド エスシタロプラムの新しい塩および固体形態
JP2021501209A (ja) * 2017-11-01 2021-01-14 コリア リサーチ インスティチュート オブ ケミカル テクノロジー エスシタロプラムを含む微粒球状徐放出注射剤及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AUST. PRESCR., vol. 39(3), JPN6026025084, 2016, pages 76 - 83, ISSN: 0005892126 *

Also Published As

Publication number Publication date
KR20240117521A (ko) 2024-08-01
US20240277654A1 (en) 2024-08-22
EP4366726A1 (en) 2024-05-15
CA3227324A1 (en) 2023-01-12
AU2022308198A1 (en) 2024-02-01
WO2023281406A1 (en) 2023-01-12
CN118284414A (zh) 2024-07-02

Similar Documents

Publication Publication Date Title
US12496300B2 (en) Methods of treating acute depression and anxiety
EP3064206B1 (en) Treatment of huntington's disease using laquinimod
TWI389689B (zh) 氟利本西林(flibanserin)於治療停經前性慾疾病之用途
AU2014261329B2 (en) Fenfluramine for use in the treatment of dravet syndrome
US11813247B2 (en) NK-1 antagonist compositions and methods for use in treating depression
AU2018364659A1 (en) Ganaxolone for use in treating genetic epileptic disoders
JP2024010018A (ja) うつ病を治療するための組成物および方法
EP4366726A1 (en) Treatment of serotonin reuptake inhibitor withdrawal syndrome
WO2024102802A1 (en) Zelatriazin for the treatment of depression
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
US20220071976A1 (en) Domperidone compositions and methods for treating depression
US20240100012A1 (en) Pharmaceutical dosage form
Van Schoor Antihistamines: a brief review: clinical
TW202541796A (zh) 用於治療失樂症的組成物及方法
WO2025096942A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
TW201919597A (zh) 利用新斯的明(neostigmine)及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法
TW200800160A (en) Prophylactic or therapeutic agent for sleep disorder
CN101304746A (zh) 氟班色林在治疗绝经前性欲障碍中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260623